Harbour BioMed Raises $221 Million in Hong Kong IPO
publication date: Dec 17, 2020
Harbour BioMed completed a $221 million Hong Kong IPO to continue its novel drug development. Headquartered in Cambridge, MA, HBM has a drug discovery CRO in Rotterdam and its own drug development operations in Suzhou. The company has built a portfolio of in-licensed late stage projects and internally developed early-stage assets in immunology and oncology. Yesterday, HBM announced it out-licensed rights for a SARS-CoV-2 neutralizing antibody to its partner AbbVie. In its first trading day, HBM's shares closed 11% lower. More details....
Stock Symbols: (HK: 02142) (NYSE: ABBV)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.